Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Karen Schneck"'
Autor:
Karen Schneck, Shweta Urva
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 3, Pp 494-503 (2024)
Abstract Tirzepatide is a first‐in‐class glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist approved as for the treatment of type 2 diabetes mellitus. A population‐based pharmacokinetic (PK) model wa
Externí odkaz:
https://doaj.org/article/fb3b81682750428da2ed990b59795c31
Autor:
BORIS CALDERON, GARRETT R. MULLINS, MICHAEL HODSDON, GRACE LI, GREG ANGLIN, SHWETA URVA, KAREN SCHNECK, JENNIFER N. BARDOS, RICARDO F. MARTINS, KATELYN BROWN
Publikováno v:
Diabetes. 71
Tirzepatide (TZP) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide (GLP) -1 receptor agonist developed for the treatment of type 2 diabetes. Patients receiving TZP may develop an immune response to the 39 amino a
Autor:
Angelyn Bethel, David A. Cox, Cheng Cai Tang, Lai-San Tham, Karen Schneck, Jeanne Geiser, Zvonko Milicevic
Publikováno v:
Diabetes. 69
Throughout the development cycle of dulaglutide, model-informed drug development (MIDD) was applied to facilitate and accelerate decision-making. Currently, dulaglutide 0.75 mg and 1.5 mg given subcutaneously once weekly (QW) is approved for the trea
Publikováno v:
Journal of Clinical Pharmacology
Insulin pharmacokinetics following subcutaneous administration were modeled, simulated, and displayed through an interactive and user‐friendly interface to illustrate the time course of administered insulins frequently prescribed, providing a simpl